Published Online
on January 25, 2007

A more recent version of this article appeared on March 1, 2007

This Article Full Text (PDF) All Versions of this Article: 38/3/1104    most recent 01.STR.0000258347.19449.0fv1 Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sanossian, N. Articles by Ovbiagele, B. Search for Related Content PubMed PubMed Citation Articles by Sanossian, N. Articles by Ovbiagele, B. Related Collections Other Stroke Treatment - Medical

Submitted on July 20, 2006
Revised on September 26, 2006
Accepted on October 3, 2006

High-Density Lipoprotein Cholesterol. An Emerging Target for Stroke Treatment

Nerses Sanossian MD^*; Jeffrey L. Saver MD; Mohamad Navab PhD; and Bruce Ovbiagele MD

From the Department of Neurology (N.S.), University of Southern California, Los Angeles, Calif; the Stroke Center and Department of Neurology (J.L.S., B.O.), University of California Los Angeles (UCLA) Medical Center, Los Angeles, Calif; the Department of Medicine (M.N.), UCLA Medical Center, Los Angeles, Calif; and the Department of Neurology (B.O.), Olive View UCLA Medical Center, Los Angeles, Calif.

^* To whom correspondence should be addressed. E-mail: sanossia{at}yahoo.com.

Background and Purpose--This review characterizes the current state of knowledge of high-density lipoprotein (HDL) in relation to stroke.

Summary of Review--HDL has anti-atherosclerotic and anti-inflammatory properties and is an important component in atherosclerosis. Serum HDL-cholesterol levels are inversely related to heart disease and stroke risk. There are various established and experimental treatments which can raise serum HDL cholesterol and improve its function.

Conclusion--HDL is an emerging target for atherosclerotic stroke treatment with the potential to dramatically impact the care of stroke patients.

Key words: cholesterol • lipids & lipoprotein • stroke

This article has been cited by other articles:

				A. Murray, C. Cluett, S. Bandinelli, A. M. Corsi, L. Ferrucci, J. Guralnik, A. Singleton, T. Frayling, and D. Melzer Common lipid-altering gene variants are associated with therapeutic intervention thresholds of lipid levels in older people Eur. Heart J., July 2, 2009; 30(14): 1711 - 1719. [Abstract] [Full Text] [PDF]

				F. M. Sacks, L. L. Rudel, A. Conner, H. Akeefe, G. Kostner, T. Baki, G. Rothblat, M. de la Llera-Moya, B. Asztalos, T. Perlman, et al. Selective delipidation of plasma HDL enhances reverse cholesterol transport in vivo J. Lipid Res., May 1, 2009; 50(5): 894 - 907. [Abstract] [Full Text] [PDF]

				G. C. Newman, H. Bang, S. I. Hussain, and J. F. Toole Association of diabetes, homocysteine, and HDL with cognition and disability after stroke Neurology, November 27, 2007; 69(22): 2054 - 2062. [Abstract] [Full Text] [PDF]